Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors
Open Access
- 6 August 2007
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 27 (6) , 775-782
Abstract
Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10−4, quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.Keywords
This publication has 20 references indexed in Scilit:
- Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinationsBlood, 2006
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood, 2006
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 2006
- BEAMing: single-molecule PCR on microparticles in water-in-oil emulsionsNature Methods, 2006
- Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistanceProceedings of the National Academy of Sciences, 2006
- BEAMing up for detection and quantification of rare sequence variantsNature Methods, 2006
- Genome sequencing in microfabricated high-density picolitre reactorsNature, 2005
- Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reactionBMC Biotechnology, 2003
- In situ localized amplification and contact replication of many individual DNA moleculesNucleic Acids Research, 1999
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990